BACKGROUND: Systemic immune activation is a strong predictor of progression of human immunodeficiency virus type 1 (HIV-1) disease and a prominent feature of infection with Mycobacterium tuberculosis. OBJECTIVE: To understand the role of systemic immune activation and microbial translocation in HIV/tuberculosis dually infected patients over the full spectrum of HIV-1 immunodeficiency, we studied circulating sCD14 and lipopolysaccharide (LPS) and their relationship to HIV-1 activity. METHODS: Two cohorts of HIV/tuberculosis subjects defined by CD4 T-cell count at time of diagnosis of tuberculosis were studied: those with low (<350/μL) and those with high (≥ 350/μL) CD4 T-cell count. Circulating soluble CD14 (sCD14) and LPS were assessed. RESULTS:Levels of sCD14 were higher in HIV/tuberculosis with high (≥ 350/μL) as compared to low CD4 T-cell count (P < .001). Whereas sCD14 levels remained elevated in HIV/tuberculosis subjects with lower CD4 T-cell counts despite treatment of tuberculosis, in HIV/tuberculosis patients with higher CD4 T-cell count (≥ 350/μL), levels declined regardless of whether highly active antiretroviral therapy (HAART) was included with the anti-tuberculosis regimen. Circulating LPS levels in HIV/tuberculosis patients with CD4 T-cell count ≥ 350/μL were unaffected by treatment of tuberculosis with or without HAART. CONCLUSION: During HIV/tuberculosis, systemic immune activation is dissociated from microbial translocation. Changes in circulating sCD14 and LPS are dependent on CD4 T-cell count.
RCT Entities:
BACKGROUND: Systemic immune activation is a strong predictor of progression of human immunodeficiency virus type 1 (HIV-1) disease and a prominent feature of infection with Mycobacterium tuberculosis. OBJECTIVE: To understand the role of systemic immune activation and microbial translocation in HIV/tuberculosis dually infectedpatients over the full spectrum of HIV-1 immunodeficiency, we studied circulating sCD14 and lipopolysaccharide (LPS) and their relationship to HIV-1 activity. METHODS: Two cohorts of HIV/tuberculosis subjects defined by CD4 T-cell count at time of diagnosis of tuberculosis were studied: those with low (<350/μL) and those with high (≥ 350/μL) CD4 T-cell count. Circulating soluble CD14 (sCD14) and LPS were assessed. RESULTS: Levels of sCD14 were higher in HIV/tuberculosis with high (≥ 350/μL) as compared to low CD4 T-cell count (P < .001). Whereas sCD14 levels remained elevated in HIV/tuberculosis subjects with lower CD4 T-cell counts despite treatment of tuberculosis, in HIV/tuberculosispatients with higher CD4 T-cell count (≥ 350/μL), levels declined regardless of whether highly active antiretroviral therapy (HAART) was included with the anti-tuberculosis regimen. Circulating LPS levels in HIV/tuberculosispatients with CD4 T-cell count ≥ 350/μL were unaffected by treatment of tuberculosis with or without HAART. CONCLUSION: During HIV/tuberculosis, systemic immune activation is dissociated from microbial translocation. Changes in circulating sCD14 and LPS are dependent on CD4 T-cell count.
Authors: Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley Journal: J Infect Dis Date: 2009-04-15 Impact factor: 5.226
Authors: C S Hirsch; Z Toossi; J L Johnson; H Luzze; L Ntambi; P Peters; M McHugh; A Okwera; M Joloba; P Mugyenyi; R D Mugerwa; P Terebuh; J J Ellner Journal: J Infect Dis Date: 2001-02-08 Impact factor: 5.226
Authors: D Goletti; D Weissman; R W Jackson; N M Graham; D Vlahov; R S Klein; S S Munsiff; L Ortona; R Cauda; A S Fauci Journal: J Immunol Date: 1996-08-01 Impact factor: 5.422
Authors: Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: C L Daley; P M Small; G F Schecter; G K Schoolnik; R A McAdam; W R Jacobs; P C Hopewell Journal: N Engl J Med Date: 1992-01-23 Impact factor: 91.245
Authors: Zuri A Sullivan; Emily B Wong; Thumbi Ndung'u; Victoria O Kasprowicz; William R Bishai Journal: EBioMedicine Date: 2015-04-01 Impact factor: 8.143
Authors: Sathyavani Subbarao; Katalin A Wilkinson; Clare L van Halsema; Suhasini Subba Rao; Tom Boyles; Netanya S Utay; Robert J Wilkinson; Graeme Meintjes Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Noor Dawany; Louise C Showe; Andrew V Kossenkov; Celia Chang; Prudence Ive; Francesca Conradie; Wendy Stevens; Ian Sanne; Livio Azzoni; Luis J Montaner Journal: PLoS One Date: 2014-02-25 Impact factor: 3.240
Authors: Samir Abdurahman; Babilonia Barqasho; Piotr Nowak; Do Duy Cuong; Wondwossen Amogné; Mattias Larsson; Lars Lindquist; Gaetano Marrone; Anders Sönnerborg Journal: J Int AIDS Soc Date: 2014-01-24 Impact factor: 5.396